Arcutis Biotherapeutics Inc (ARQT)
NASDAQ:ARQT
Want to see ARQT full AI Analyst Report?
ARQT Stock Chart & Stats
$24.53
-$0.25(-1.59%)
At close: 4:00 PM EST
$24.53
-$0.25(-1.59%)
Day’s Range― - ―
52-Week Range$12.72 - $31.77
Previous CloseN/A
Volume446.87K
Average Volume (3M)1.74M
Market Cap
$2.61B
Enterprise Value$2.59B
Total Cash (Recent Filing)$224.00M
Total Debt (Recent Filing)$13.20M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Jul 30, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding125,083,374
10 Day Avg. Volume2,360,347
30 Day Avg. Volume1,736,441
Financial Highlights & Ratios
PEG Ratio2.58
Price to Book (P/B)19.50
Price to Sales (P/S)9.82
P/FCF Ratio-585.47
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue6.23
Enterprise Value/Gross Profit6.85
Enterprise Value/Ebitda202.59
Forecast
1Y Price Target
$34.86Price Target Upside42.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.2
Revenue Forecast (FY)$496.90M
Bulls Say, Bears Say
Bulls Say
Commercial PerformanceZoryve prescription volumes exceeded expectations, prompting management to raise net product revenue guidance and underpinning continued positive cash flow generation.
Pipeline And Label ExpansionPlanned label expansions into pediatric use and advancement of clinical programs in vitiligo and hidradenitis suppurativa expand the product's addressable market and long-term revenue potential.
Sales Force ExpansionExpansion of the dermatology sales force with focused outreach to high-volume primary care doctors and pediatricians is expected to broaden patient access and accelerate prescription adoption.
Bears Say
Product Concentration RiskMaterial concentration risk exists because Zoryve is the company's sole commercial asset, leaving the business vulnerable if uptake slows or competitors win formulary position.
Revenue HeadwindsExpected revenue step-down from deductible resets, increased copay use, channel inventory unwind, and weather-related disruption could temporarily depress realized sales.
Rising Expense AssumptionsAnalyst models reflect higher research and selling expense assumptions to support clinical development and a larger sales force, which weighs on near-term profitability.
Arcutis Biotherapeutics News
ARQT FAQ
What was Arcutis Biotherapeutics Inc’s price range in the past 12 months?
Arcutis Biotherapeutics Inc lowest stock price was $12.72 and its highest was $31.77 in the past 12 months.
What is Arcutis Biotherapeutics Inc’s market cap?
Arcutis Biotherapeutics Inc’s market cap is $2.61B.
When is Arcutis Biotherapeutics Inc’s upcoming earnings report date?
Arcutis Biotherapeutics Inc’s upcoming earnings report date is Jul 30, 2026 which is in 63 days.
How were Arcutis Biotherapeutics Inc’s earnings last quarter?
Arcutis Biotherapeutics Inc released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.064 by -$0.026.
Is Arcutis Biotherapeutics Inc overvalued?
According to Wall Street analysts Arcutis Biotherapeutics Inc’s price is currently Undervalued.
Does Arcutis Biotherapeutics Inc pay dividends?
Arcutis Biotherapeutics Inc does not currently pay dividends.
What is Arcutis Biotherapeutics Inc’s EPS estimate?
Arcutis Biotherapeutics Inc’s EPS estimate is 0.04.
How many shares outstanding does Arcutis Biotherapeutics Inc have?
Arcutis Biotherapeutics Inc has 125,083,374 shares outstanding.
What happened to Arcutis Biotherapeutics Inc’s price movement after its last earnings report?
Arcutis Biotherapeutics Inc reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.064. Following the earnings report the stock price went down -14.522%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics Inc?
Currently, no hedge funds are holding shares in ARQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcutis Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.86 (42.10% Upside)
$34.86 (42.10% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 481.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
49.57%
12-Months-Change
Fundamentals
Return on Equity
-1.41%
Trailing 12-Months
Asset Growth
33.68%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
ARQT Company Deck
ARQT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call described strong underlying commercial momentum and meaningful clinical and pipeline progress: 65% YoY revenue growth, share gains, positive operating cash flow, pediatric submissions, and initiation of ARQ-234 Phase I. These positives are tempered by a seasonality- and weather-driven Q1 demand dip (-6% QoQ for ZORYVE), continued material gross-to-net pressure (in the 50s), near-term SG&A/R&D increases, and limited Part D coverage today. Management emphasized that recent investments (sales force expansion, PCP/pediatric build, DTC) will drive demand in H2 2026 and a larger inflection in 2027, and they maintained full-year guidance of $480M–$495M.View all ARQT earnings summariesARQT Stock 12 Month Forecast
Average Price Target
$34.86
▲(42.10% Upside)
Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
9.11% Insiders
16.00% Mutual Funds
52.40% Other Institutional Investors
8.80% Public Companies and
Individual Investors